Skip to content

Efficacy and Acceptability of Thermal Ablation in the Treatment of Cervical Neoplasia

Efficacy and Acceptability of Thermal Ablation in the Treatment of Cervical Neoplasia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05453318
Enrollment
119
Registered
2022-07-12
Start date
2017-10-17
Completion date
2020-08-17
Last updated
2022-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Neoplasm

Brief summary

Longitudinal study in two referral centers in Morocco to evaluate the effectiveness, the acceptability and safety of thermal ablation in the treatment of cervical neoplasia.

Detailed description

The study population consisted of women with a positive Visual Inspection with Acetic Acid (VIA) screening test referred for ablative treatment. A total of 119 women with lesions eligible to ablative treatment were counselled and treated by thermal ablation. Informed consent was signed by each participant. Just after treatment, the patients were inquired about the level of pain during the procedure, and their level of satisfaction with the treatment. The women were followed-up at 6 weeks for any complication and re-assessed by colposcopy and biopsy at 12 months for any persistent or recurrent lesion and for any adverse event.

Interventions

Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.

Sponsors

Referral Centre of Reproductive Health, Fez, Morocco
CollaboratorUNKNOWN
Referral Centre of Reproductive Health, Taza, Morocco
CollaboratorUNKNOWN
International Agency for Research on Cancer
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is a single arm study where women presenting with cervical lesions eligible to ablation were treated and followed-up for cure and adverse events.

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Women having been screened positive at VIA at the primary health center and referred to the diagnosis centre of Fez and Taza for ablative treatment by thermal ablation

Exclusion criteria

* Lesion occupying the 4 quadrants of the cervix * Not visible squamous columnar junction (not Type 1 TZ (transformation zone)) * Vaginal or endocervical lesion * Lesion subjective of cervical cancer

Design outcomes

Primary

MeasureTime frameDescription
Cure rate based on colposcopy and histology assessment1 yearCure rate is assessed after 1 year of treatment by colposcopy. Persistent or recurrent lesions are treated by thermal ablation, excision or hysterectomy according to the lesion size and characteristics.

Secondary

MeasureTime frameDescription
Acceptability of thermal ablation in terms of adverse events1 yearInformation on adverse events are collected immediately after the treatment, at the 6-week visit (short-term adverse events) and at the 12-month visit. Any minor and moderate complications are inquired.
Acceptability of thermal ablation in terms of satisfaction levelWithin one hour after procedureAcceptability of thermal ablation is also measured by the satisfaction levelusing a nine-level Likert scale (from 1. Very unsatisfied to 9. Verysatisfied), through administration of a questionnaire just after treatment.
Safety of TA in terms of major adverse events1 yearInformation on adverse events are collected immediately after the treatment, at the 6-week visit (short-term adverse events) and at the 12-month visit. Any major complications (i.e. necessitating hospitalization) were inquired.

Countries

Morocco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026